ClinicalTrials.gg
CompletedNCT06320106Updated Nov 10, 2026

Assessment of Navigation Abilities in Children With Cerebral Palsy and Their Peers

An interventional study of Virtual Reality baseline assessment in Cerebral Palsy and Healthy Volunteers, sponsored by IRCCS Eugenio Medea. Completed at 1 site in Italy. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by IRCCS Eugenio Medea · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2023, registered Mar 2024).
Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
13 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Cerebral Palsy by IRCCS Eugenio Medea — 8 open to participants now, 8 under way, none of them phase 3. Cerebral Palsy · IRCCS Eugenio Medea.

Enrollment
8th of 11
37 · median 44
Started
2023
with 2 others
No phase
11 of 18
6 open now
Registered
9th of 18
by date

Among the 18 studies in Cerebral Palsy by IRCCS Eugenio Medea, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2023, is one of 11 with no phase, and was the 9th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

8 of the 18 studies in Cerebral Palsy by IRCCS Eugenio Medea are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 13 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Cerebral Palsy by IRCCS Eugenio Medea, or all of them as a file.
02

Study summary

Spatial navigation skills are very important in everyday activities and quality of life but spatial navigation abilities are not part of the standard process of assessment and rehabilitation of patients. Furthermore, it is known that children with cerebral palsy have impaired visuo-spatial competences. The main objective of this study is to evaluate and compare the spatial navigation abilities of typically developing children and of children with cerebral palsy using the "StarMaze" application delivered by means of a Head Mounted Display (HMD). The second aim is to investigate the user experience during the session. A similar application was already developed and tested in a virtual reality large scale platform whose size and cost limit the accessibility. Therefore, the assessment (and future training) of navigation abilities with affordable and easy-to-use technology such as HMD open new perspectives.

03

Conditions studied

  • Cerebral Palsy
  • Healthy Volunteers

Browse trials for

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IQ higher than 70

Exclusion criteria

Exclusion Criteria:

  • Subjects with epileptic issues
  • Subjects with poor head control
  • Visual acuity not correctable with eyeglasses
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    CP group

    Participants with cerebral palsy are recruited.

    Other: Virtual Reality baseline assessment

  • Experimental
    TD group

    Typically developing children are recruited.

    Other: Virtual Reality baseline assessment

Interventions

  • OtherVirtual Reality baseline assessment

    They undergo a baseline assessment (including cognitive level and pen and paper tests for visuo-spatial abilities). Then they perform a spatial navigation assessment with an immersive virtual reality application delivered by the Oculus Quest viewer. The spatial navigation application consists of a 5-way star-maze adapted from (Biffi et al 2020 Front. Psychol.) where the participants have to find a treasure hidden at the end of one way. The application measures both the learning of spatial information and the strategy used (egocentric or allocentric). After the session, the participants fill questionnaires related to cyber-sickness and usability of the application.

06

What researchers measure

Primary outcomes

  1. Navigation strategy

    The navigation strategy is measured by the application "StarMaze" delivered by the Oculus Quest viewer and it could be egocentric or allocentric. The strategy is egocentric if the participant finds the treasure in the virtual space by using a self-centred trajectory. The strategy is allocentric if the participant find the treasure in the virtual space by using a trajectory based on environmental cues.

    Time frame: One day

Secondary outcomes

  1. Learning rate

    The learning rate of correct path to follow to find the treasure strategy is measured by the application "StarMaze" delivered by the Oculus Quest viewer. It is the number of trials required by the participant to reach a stable performance

    Time frame: One day

  2. Simulator Sickness Questionnaire

    The questionnaire evaluates the effects of cyber sickness. Participants have to score 16 symptoms on a four-point scale (0-3).The symptoms can be placed into three general categories: oculomotor, disorientation, and nausea. Weights are assigned to each of the categories and summed together to obtain a single score.

    Time frame: One day

  3. System Usability Scale

    It evaluates the usability of the system. The SUS is a simple, ten-item five-point Likert scale giving a global view of subjective assessments of usability.

    Time frame: One day

  4. Independent Television Commission-Sense of Presence Inventory

    It is a 5-point Likert scale, composed of 44 items. This questionnaire evaluates the user experience to understand if the person enjoyed the game, the setting, and the overall experience. In particular, the questionnaire addresses four factors: spatial presence, engagement, realness of the environment, and side effects (cyber sickness).

    Time frame: One day

  5. Suitability Evaluation Questionnaire - simplified version

    It evaluates the sense of agency with four questions (likert scale 1-5) and one open question.

    Time frame: One day

  6. Short-form of PANAS-Positive Affect and Negative Affect Scales

    In the questionnaire, the participant must evaluate how much s/he feels in the way described by the adjective when filling out the questionnaire, responding on a 5-point Likert scale. The PANAS provides measures of Positive Affects (PAs) and Negative Affects (NAs). The PA and NA scores are the sums of the ratings of the PA items and the NA items, respectively. PA indicates the level of pleasurable engagement with the product while NA is a general factor of subjective distress.

    Time frame: One day

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Oct 2026, 44 months.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's 44 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Oct 2026 and completion Dec 2026 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 20, 2024
StartActual
Feb 7, 2023
Primary completionActual
Oct 28, 2026was Dec 2026
CompletionActual
Oct 28, 2026was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 10, 2026
Primary completion
Dec 31, 2026→Oct 28, 2026 (actual)
Nov 10, 2026
Study completion
Dec 31, 2026→Oct 28, 2026 (actual)
Nov 10, 2026
Enrollment
26 (estimated)→37 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2026→Oct 28, 2026 (now actual)
    Study completion Dec 31, 2026→Oct 28, 2026 (now actual)
    Enrollment 26 (estimated)→37 (actual)
    + 5 other changes: identifiers, verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06320106
Responsible party
Sponsor
First posted
Mar 20, 2024
Start date
Feb 7, 2023
Primary completion
Oct 28, 2026
Completion
Oct 28, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion